User:Judika39/Nzedegwu Robert Olisa

Nzedegwu Robert Olisa, III  is an American Molecular Biologist from El Paso, Texas and the inventor of Braunmycin,   a ferric or ferrous iron methylated thiolate (Methiolate) reductase. Braunmycin is an organic adjuvant used to supplement treatment of cancers fueled by microbes, and AIDS. Olisa was born in 1967 at Onitsha, Nigeria, but shortly thereafter immigrated to the US in 1971 as an infant. His mother, a retired librarian and father, a German trained,Cambridge educated Pathologist and a former Howard University professor of Pathology named him after his great, great, great grandfather Nzedegwu I of Ossomala (1830-1854)  ,and grandfather Nzedegwu II of Ossomala,Robert Olisa, MBE (1895-1999),. He is a great great nephew of Omu Okwei of Ossomari (1872-1943), ,and a nephew to Professor Kenneth Dike by marriage on his paternal side. Olisa is Founder and Owner of Olisa Research (Formerly Biological Agents Corporation USA, or BAC), a fiduciary of the Texas non-profit Olisa Foundation. The foundation trades as American Journal of Biological Defense,. Olisa is a pioneer of applied Proteomics, and Computational Biology. He has a United States patent and several United States Library of Congress copyrights in this area. , . Before obtaining Master’s degrees in Biological Sciences (1996) from the University of Texas at El Paso and Public Administration (2006) at the Institute for Policy and Economic Development,University of Texas El Paso he obtained a diploma in Medical Technology from US Army Academy Health Sciences, Fort Sam Houston, San Antonio Texas. He was an aspiring doctoral student at Open University, San Diego State University in California (1997), Howard University in Washington DC (1998-2003), and at the University of Tuebingen, Germany where he studied under Volkmar Braun (2002-2004). In 2008, he and his legal team issued  ‘cease and desist’ letters to several academic and corporate institutions in the United States and Europe for Copyrights and Patent infringements of his proteomics technologies. In addition, in 2008 they filed complaints with the Federal Bureau of Investigations (FBI), National Science Foundation (NSF), and National Institutes of Health (NIH). Olisa’s private foundation develops and distributes alternative immunotherapeutics and prophylaxis for cancer and contagion risk management in developing countries.

United States military
Olisa enlisted in the US Army in 1993, and performed basic infantry training at Ft. Leonard Wood, Missouri, and Advanced Training as a Medical Technologist at US Army Academy Health Sciences, Fort Sam Houston, San Antonio Texas. After selection for officer candidacy, he attended Officer Indoctrination School (OIS)at the Officer Training Command at New Port, Rhode Island and received a direct commission in the United States Navy Medical Services Corps in 1996. He transferred into the Naval Reserves in 1998. He has performed tours of duty in the Europe, Latin America, Africa and was awarded the Armed Forces Expeditionary Medal in 1996 in recognition of his service in the Middle East. Occupations practiced in the Naval Reserves by Olisa include Microbiologist, Industrial Hygiene Officer, Environmental Health Officer, and Healthcare Administrator. .

Early education
Olisa started his education by attending St. Catherine’s Laborè (grade school) Wheaton Maryland, USA (1972-1977), Our Lady of Fatima School, Jos, Nigeria (1977-1978), and St Judes School Jos, Nigeria (1978). He attended Saint Joseph’s College (middle school) Vom, Nigeria (1978-1980), Federal Government College (high school), Jos, Nigeria (1980-1983), Uthman Dan Fodio University Sokoto, Nigeria (1984). Olisa briefly studied Medicine at the University of Jos Nigeria in 1985 but transferred to the Natural Sciences where he received an undergraduate degree in Zoology in 1990. During this time, while in Africa in the ‘80s, he developed an interest in HIV/AIDS research. After graduation he enlisted info the United States Army in 1993.

Discovery and invention
Olisa started his research corporation in 1998 while attending graduate school at the San Diego State University. His first invention was originally based on a United States Department of Defense research project which he wanted to convert to a thesis proposal for graduate work at the San Diego State University. During this time he created a standard online algorithm for contagions risk management. His algorithm has been packaged into software that is currently marketed as the SurgeForcast1.0. In 2007 he was awarded the first US patent issued for a utility in proteomics (US patent 7,244,702 was filed in April 23, 2003). In summary, the patent is for the invention of a new biochemical (Braunmycin) and a its usefulness in the process of proteomics. The patent also includes the discovery of new composition of matter called Olisferrol (NAFDAC Reg No. A7-0694L)associated with his invention. The original idea of this invention was based on his doctoral research at Howard University in Washington DC and University of Tuebingen in Germany. In 2002, while he working for his research corporation  at the dorm rooms of Howard University he invented and formulated a biochemical for iron-affinity chromatography named braunmycin (C6H12FeN06) after Volkmar Braun. Additionally, while at Howard University he developed a technique for purifying and characterizing iron-binding proteins in DNA cells using braunmycin and partial genomic and proteomic databases available at the time. For his effort in 2002 he was awarded both the Charles Ireland first place Prize for medical research by the Howard University Hospital and a National General Meeting Travel Grant by the American Society for Microbiology to present his research. Seven years later the United States Government awarded him a patent for utilities associated with his discoveries and invention. While studying abroad as a guest doctoral student in Germany he discovered Olisferrol (C119H163Fe2N29071S4) or Ferrous Methiolate an organic supplement that can be derived from and identical to Echinacea and Goldenseal root extracts that support the immune system in independent clinical and animal studies. , . Collectively, his pharmaceutical and medical technologies are currently used in early cancer detection, immune therapeutics, and contagions risk management.

Writings
His book, Biological Agents Index: Risk Management Strategies for Contagions [ISBN 978-0-9815543-4-1]is in its fourth edition and is published by American Journal of Biological Defense (ISSN 1941 4048). The book is based on concepts in Macroeconomics and their uses in Medicine.